Loading...

Austar Lifesciences Limited

6118.HK•HKSE
Healthcare
Medical - Devices
HK$1.42
HK$0.05(3.65%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Austar Lifesciences Limited achieved steady financial progress, growing revenue from $1.10B in Q2 2022 to $700.92M in Q2 2024. Gross profit stayed firm with margins at 21% in Q2 2024 versus 21% in Q2 2022. Operating income totaled $17.25M in Q2 2024, maintaining a 2% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $28.61M. Net income rose to $5.88M, with EPS at $0.01. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;